Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration
Advanced Science · 2026-05 · 13 (27)
DOI: 10.1002/advs.202518026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 05.03.2026. Verfasst von Salwa Suliman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Dentistry, Faculty of Medicine, Centre For Translational Oral Research (TOR), University of Bergen, Bergen, Norway. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Bone Regeneration, Osteogenesis, Eicosapentaenoic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Trond Mohn Foundation, Research Council of Norway, Norges Forskningsråd.
Abstract (Originalsprache)
The bone regenerative potential of bone marrow‐derived mesenchymal stromal/stem cells (MSC) is critically shaped by their interaction with the host immune system. Here, we compare two MSC priming strategies: coculture with regulatory T cell (Treg) or exposure to the proresolving mediator Resolvin E1 (RvE1) to enhance ectopic osteogenesis in mice. Both approaches enhance MSC‐mediated bone formation through distinct local and systemic immunomodulatory mechanisms. Treg priming promotes a regulated anti‐inflammatory environment characterized by reduced IL‐6 protein levels (3.6‐fold), sustained IL‐13 elevation up to 10 weeks (1.5‐fold compared with RvE1), early suppression of cytotoxic CD8 + T cells and IFN‐γ production by CD4 + T cells in lymph nodes, a >25% reduction in fibrous capsule formation, and enhanced B cell activity, collectively supporting ossification. In contrast, RvE1 priming promotes early TNF‐α and late granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) production (1.2‐fold compared with Treg) within the scaffold, facilitating osteoblast maturation. Transcriptomic profiling revealed distinct osteogenic signatures, with amphiregulin uniquely upregulated in the Treg group (>7‐fold). Using a Treg depletion model, we further demonstrate that RvE1 retains partial immunomodulatory capacity and supports matrix organization. Together, these findings underscore the versatility of immune modulation in directing MSC fate and highlight the potential of tailoring immunoregulatory strategies to optimize bone regeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Dentistry, Faculty of Medicine, Centre For Translational Oral Research (TOR), University of Bergen, Bergen, Norway.
- The ADA Forsyth Institute, Cambridge, Massachusetts, USA.
- Oral Biology Department, School of Dental Medicine, University at Buffalo, Buffalo, New York, USA.
- Genome Core Facility, Department of Clinical Science, University of Bergen, Bergen, Norway.
- Department of Developmental and Surgical Sciences, School of Dentistry, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Salwa Suliman
Förderung
- Trond Mohn Foundation
- Research Council of Norway
- Norges Forskningsråd
Zitieren
APA
Suliman, S., Rivas, C. A., Srivastava, A., Marek, N., Mustafa, K., & Kantarci, A. (2026). Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration. Advanced Science, 13(27). https://doi.org/10.1002/advs.202518026
Vancouver
Suliman S, Rivas CA, Srivastava A, Marek N, Mustafa K, Kantarci A. Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration. Advanced Science. 2026;13(27). doi:10.1002/advs.202518026
BibTeX
@article{Suliman2026,
author = {Suliman, Salwa and Rivas, Carla Alvarez and Srivastava, Aashish and Marek, Nora and Mustafa, Kamal and Kantarci, Alpdogan},
title = {Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {27},
doi = {10.1002/advs.202518026}
}
EUVIMED